Plain-English translation of NCT06123377 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a simple blood test—measuring two markers called sFlt-1 and PIGF—can help doctors make better decisions about when to safely deliver babies in pregnant women with gestational hypertension (high blood pressure during pregnancy). Right now, doctors typically recommend delivery at 37 weeks as a precaution, but this study is investigating whether the blood test results could allow some women to safely wait until 39 weeks, which may benefit the baby's development.
High blood pressure in pregnancy is a serious condition that can harm both mother and baby, but current guidelines for when to deliver are based on older information. Doctors hope that measuring these specific blood markers will help them identify which women can safely carry their pregnancy longer and which ones need earlier delivery—giving each baby the best chance at a healthy outcome.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will have weekly blood tests to measure the two markers and regular check-ins with your doctor. Depending on which group you're assigned to, your doctor will plan your baby's delivery either at 37 weeks or 39 weeks—both considered safe times. Throughout your participation, your health and your baby's health will be carefully monitored to ensure everything is going well.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
Panama